Aradigm (US) gets computer inhaler patent:
This article was originally published in Clinica
Executive Summary
Aradigm (US) has received a US patent for its inhalation-regulated pulmonary drug delivery system. The microprocessor-controlled device uses data on breathing to time drug delivery precisely via an inhaler. Manually activated inhalers often deliver erratic doses because patients are not able to discharge them at the optimum time. Aradigm is developing two hand-held aerosol delivery devices: SmartMist for asthma management; and AERx for delivering systemic drugs which are normally injected. The company has six US patents granted and a further 21 under review.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.